Samsung Bioepis’ Ontruzant (trastuzumab) biosimilar version of Herceptin has become the first biosimilar to be prequalified by the World Health Organization in a move that the WHO says “could make this expensive, life-saving treatment more affordable and available to women globally.”
Noting that trastuzumab was included in the WHO essential medicines list in 2015 as an essential treatment for about 20%...






